| Title: |
Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center |
| Authors: |
Rotundo M. S.; Zampino M. G.; Ravenda P. S.; Bagnardi V.; Peveri G.; Dell'Acqua V.; Surgo A.; Trovato C.; Bottiglieri L.; Bertani E.; Petz W. L.; Fumagalli Romario U.; Fazio N. |
| Contributors: |
Rotundo, M; Zampino, M; Ravenda, P; Bagnardi, V; Peveri, G; Dell'Acqua, V; Surgo, A; Trovato, C; Bottiglieri, L; Bertani, E; Petz, W; Fumagalli Romario, U; Fazio, N |
| Publisher Information: |
SAGE Publications Inc. |
| Publication Year: |
2020 |
| Collection: |
Università degli Studi di Milano-Bicocca: BOA (Bicocca Open Archive) |
| Subject Terms: |
anal cancer; capecitabine; chemotherapy; cisplatin; image-guided; intensity-modulated; radiotherapy; squamous cell neoplasm |
| Description: |
Background and Aims: The standard treatment of non-metastatic anal squamous cell carcinoma (ASCC) consists of chemotherapy with mitomycin (MMC) plus 5-fluorouracil (5FU) for 1–2 cycles concomitant with pelvic radiotherapy. Subsequent studies introduced cisplatin (CDDP) combined with 5FU, with unclear results. We evaluated the doublet capecitabine (C) and CDDP as a possible alternative to MMC-5FU regimen concomitant with intensity-modulated radiation therapy (IMRT). Patients and Methods: We carried out a retrospective study on 67 patients affected by stage I–III ASCC, treated with CDDP (60–70 mg/m2 every 21 days for two courses) plus C (825 mg/m2 twice daily for 5 days/week) chemotherapy concomitant with IMRT for curative intent. Results: At a median follow up of 41 months, the clinical complete response calculated at the 6-month time-point (6-moCR), the 6-month objective response rate and the 6-month disease control rate were 93%, 94%, and 99%, respectively. Disease-free survival rates at 1, 2, and 3 years were 89%, 87%, and 85%, while the overall survival rates at 1 and 2 years were 100% and 95%. The colostomy-free survival rates were 90% at 1 year and 88% at 2 years. Grade 3–4 acute adverse events were reported in 61% of patients; predominantly skin toxicity (46%) and limited hematological toxicity (12%). Conclusion: In this retrospective study, chemotherapy with C plus CDDP concomitant with IMRT proved safe and effective, and may represent a possible alternative option to standard MMC-containing regimen for curative intent. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/32728394; info:eu-repo/semantics/altIdentifier/wos/WOS:000553804900001; volume:12; journal:THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY; https://hdl.handle.net/10281/295381 |
| DOI: |
10.1177/1758835920940945 |
| Availability: |
https://hdl.handle.net/10281/295381; https://doi.org/10.1177/1758835920940945 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative Commons ; license uri:http://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.8244A570 |
| Database: |
BASE |